Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa

Excerpt from the Press Release:

SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, April 05, 2023 (GLOBE NEWSWIRE) — Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections. Given the positive safety and tolerability profile, the study will now enroll patients into the expansion cohort, using the highest dose evaluated in the study to explore the potential efficacy of the compound.

The phase 1/2a study is conducted in collaboration with Endogena’s Lead Investigator, Mark Pennesi, MD, Ph.D., Professor of Ophthalmology at the Casey Eye Institute in Oregon, USA, to examine the safety, tolerability and preliminary efficacy of EA-2353 administered by intravitreal injection in patients with RP (ClinicalTrials.gov identifier: NCT05392751). A total of 14 patients with RP due to any pathologic genetic mutation are being recruited across up to six sites in the USA. The first patient was dosed in July 2022 and 9 patients have been treated to date during the dose escalation phase.
EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function.

Click the button below to read the entire Press Release:

Continue Reading The Press Release